Call us today: +1 (304) 470-2225
English
You can use WPML or Polylang and their language switchers in this area.
0 $0.00

Cart

No products in the cart.

View Cart Checkout

Menu

Business

Home » Business
IDHI Mutation AML

How Acute myeloid leukaemia (AML) Clinical Landscape is transforming for IDH1 or IDH2 mutated patients? Key comments from ASH 2022

Business by Mellalta Meets Analyst Leave a Comment on How Acute myeloid leukaemia (AML) Clinical Landscape is transforming for IDH1 or IDH2 mutated patients? Key comments from ASH 2022

Acute myeloid leukaemia is a genetically heterogeneous hematologic malignancy in which approximately 8% and 12% of acute myeloid leukemias harbour an IDH1 or IDH2 mutation, respectively.  A generally inferior outcome is seen with IDH1 mutations […]

Read More

Latest Cast Studies

Artificial Intelligence Diagnostic Tool–Due Diligence for Collaboration

Robot-Assisted Surgical System–MedTech Market Intelligence

Anti-Infective–Market Access Strategies 

Upcoming Events

Close Menu